While oligonucleotide-based drugs have demonstrated significant promise, the ability to unlock the ultimate potential of this therapeutic approach has been limited by key delivery challenges.
Limitations of Conventional Delivery Technology
Oligonucleotides are associated, with high instability, low bioavailability, and poor cellular uptake, making their delivery to targeted cells/tissues in the body a significant challenge.
NapaJen’s Targeted Delivery Solution
To address these challenges and harness the full promise of this drug class, NapaJen has developed a novel immune cell-targeted oligonucleotide delivery technology.